Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

SourceRE and Hive MLS Catch Major Vendors Circumventing MLS in Groundbreaking Forensic Pilot

April 21, 2026

The System Missing Between Field Operations and Finance Is Here

April 21, 2026

Tim Cook was an innovator — just not the Jobs kind

April 21, 2026

DLP Capital Appoints Eli Marshall to Lead Strategic Relationships and Organizational Growth

April 21, 2026

The Ungoverned Workforce: Cybersecurity Insiders Finds 92% Lack Visibility Into AI Identities

April 21, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Europe Clinical Biomarkers Market Analysis and Forecast Report 2024, Featuring ALCEN, bioMerieux, Centogene, Eurofins Scientific, F. Hoffmann-La Roche and Qiagen
Press Release

Europe Clinical Biomarkers Market Analysis and Forecast Report 2024, Featuring ALCEN, bioMerieux, Centogene, Eurofins Scientific, F. Hoffmann-La Roche and Qiagen

By News RoomJuly 19, 20243 Mins Read
Europe Clinical Biomarkers Market Analysis and Forecast Report 2024, Featuring ALCEN, bioMerieux, Centogene, Eurofins Scientific, F. Hoffmann-La Roche and Qiagen
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, July 19, 2024 (GLOBE NEWSWIRE) — The “Europe Clinical Biomarkers Market – Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.

The European clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033.

Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.

The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services.

Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe’s regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess.

This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.

Key Market Trends

  • Integration of Artificial Intelligence in Biomarker Discovery
  • Increasing Biomarkers Usage in Precision Medicine
  • Technologies Being Used in Clinical Biomarker Testing
  • Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

Market Segmentation

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Some prominent names established in this market are

  • ALCEN
  • bioMerieux
  • Centogene
  • Eurofins Scientific
  • F. Hoffmann-La Roche
  • QIAGEN

Key Attributes:

Report Attribute Details
No. of Pages 70
Forecast Period 2023 – 2033
Estimated Market Value (USD) in 2023 $7.19 Billion
Forecasted Market Value (USD) by 2033 $14.84 Billion
Compound Annual Growth Rate 7.5%
Regions Covered Europe

Key Topics Covered:

Executive Summary

1 Market
1.1 Product Definition
1.2 Inclusion and Exclusion

2 Market Scope
2.1 Key Questions Answered in the Report

3 Research Methodology

4 Market Overview
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region
5.1 Overview
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 U.K.
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest-of-Europe

6 Market – Company Profiles

  • ALCEN
  • bioMerieux S.A.
  • CENTOGENE N.V.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V

For more information about this report visit https://www.researchandmarkets.com/r/m4yqtw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • European Clinical Biomarkers Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

SourceRE and Hive MLS Catch Major Vendors Circumventing MLS in Groundbreaking Forensic Pilot

The System Missing Between Field Operations and Finance Is Here

DLP Capital Appoints Eli Marshall to Lead Strategic Relationships and Organizational Growth

The Ungoverned Workforce: Cybersecurity Insiders Finds 92% Lack Visibility Into AI Identities

Patriot Mobile joins America First Policy Institute for America’s 250th Celebration in Fort Worth, Texas

Intermountain Health Primary Children’s Hospital in Lehi, Utah is Already Expanding

Murder, Corruption, and Betrayal Unravel in Chicago’s Dark Underbelly. New Fiction From Palmetto Publishing

Jelly Lean (URGENT REPORT) Is It Legit? Complaints, Official Website, Studies, Ingredients, Benefits, and Customer Warnings

MemoPryl Claims Evaluated: What the Cognitive Enhancement Research Says About MemoPryl Supplementation for Brain Health

Editors Picks

The System Missing Between Field Operations and Finance Is Here

April 21, 2026

Tim Cook was an innovator — just not the Jobs kind

April 21, 2026

DLP Capital Appoints Eli Marshall to Lead Strategic Relationships and Organizational Growth

April 21, 2026

The Ungoverned Workforce: Cybersecurity Insiders Finds 92% Lack Visibility Into AI Identities

April 21, 2026

Latest News

Patriot Mobile joins America First Policy Institute for America’s 250th Celebration in Fort Worth, Texas

April 21, 2026

Intermountain Health Primary Children’s Hospital in Lehi, Utah is Already Expanding

April 21, 2026

Murder, Corruption, and Betrayal Unravel in Chicago’s Dark Underbelly. New Fiction From Palmetto Publishing

April 21, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version